# Clinical Investigation Plan Template

**Regulatory Reference**: ISO 14155:2020, EU MDR Annex XV
**Template Version**: 1.0.0
**Last Updated**: 2025-02-09
**Valid For**: Clinical Investigation of Medical Devices

---

## Document Information

| Field | Value |
|-------|-------|
| **Investigation Title** | [Enter investigation title] |
| **Device Name** | [Enter device name] |
| **Sponsor** | [Enter sponsor name] |
| **Investigation Version** | [Enter version number] |
| **Date of Issue** | [Enter date] |
| **Investigational Product** | [Device description] |
| **Investigator(s)** | [Enter investigator names] |
| **Study Sites** | [Enter study sites] |

---

## Protocol Signature Page

| Role | Name | Signature | Date |
|------|------|-----------|------|
| **Principal Investigator** | | | |
| **Co-Investigator(s)** | | | |
| **Sponsor Representative** | | | |
| **Medical Monitor** | | | |
| **Statistician** | | | |

---

## Revision History

| Version | Date | Changes | Author |
|---------|------|---------|--------|
| 1.0 | [Date] | Initial protocol | [Name] |

---

## Table of Contents

1. [General Information](#1-general-information)
2. [Investigation Objectives](#2-investigation-objectives)
3. [Investigation Design](#3-investigation-design)
4. [Subject Selection](#4-subject-selection)
5. [Investigational Plan](#5-investigational-plan)
6. [Investigational Product](#6-investigational-product)
7. [Safety Assessment](#7-safety-assessment)
8. [Effectiveness Assessment](#8-effectiveness-assessment)
9. [Statistical Considerations](#9-statistical-considerations)
10. [Data Collection and Management](#10-data-collection-and-management)
11. [Ethical Considerations](#11-ethical-considerations)
12. [Quality Control and Assurance](#12-quality-control-and-assurance)
13. [Handling of Investigational Product](#13-handling-of-investigational-product)
14. [Records and Reports](#14-records-and-reports)
15. [Publication Policy](#15-publication-policy)
16. [Appendices](#16-appendices)

---

## 1. General Information

### 1.1 Sponsor Information

| Field | Details |
|-------|---------|
| **Sponsor Name** | [Enter sponsor name] |
| **Sponsor Address** | [Enter address] |
| **Sponsor Contact** | [Name, phone, email] |
| **Medical Monitor** | [Name, credentials, contact] |
| **Quality Assurance Contact** | [Name, contact] |

### 1.2 Regulatory Information

| Field | Details |
|-------|---------|
| **Clinical Trial Authorization** | [CT number if applicable] |
| **Ethics Committee Approval** | [EC approval number] |
| **Notified Body** | [NB name and number] |
| **Investigation Classification** | [MDD/MDR risk class] |
| **Device Classification** | [Class I, IIa, IIb, III] |
| **Investigation Type** | [Pivotal, Feasibility, First-in-Human] |
| **GCP Compliance** | [Yes - ISO 14155:2020] |

### 1.3 Investigation Summary

**Title**: [Full investigation title]

**Brief Description**:

[Provide 2-3 paragraph summary of the investigation including:

- Device and intended use
- Investigation objectives
- Study design overview
- Target population
- Duration]

### 1.4 Investigational Product

| Attribute | Details |
|-----------|---------|
| **Device Name** | [Enter device name] |
| **Model Number(s)** | [Enter model numbers] |
| **Device Description** | [Brief description] |
| **Intended Use** | [Per IFU] |
| **Comparator** | [Active, placebo, standard of care] |
| **Indications** | [Enter indications] |
| **Contraindications** | [Enter contraindications] |

### 1.5 Investigational Sites

| Site ID | Site Name | Investigator | Address | Target Enrollment |
|---------|-----------|--------------|---------|-------------------|
| [Site 1] | [Hospital/Clinic] | [Dr. Name] | [Address] | [N] |
| [Site 2] | [Hospital/Clinic] | [Dr. Name] | [Address] | [N] |

---

## 2. Investigation Objectives

### 2.1 Primary Objective

[State the primary objective clearly and measurably]

**Example**: To evaluate the safety and effectiveness of [Device] compared to [Comparator] for [indication] as measured by [primary endpoint] at [timepoint].

### 2.2 Secondary Objectives

1. [Secondary objective 1]
2. [Secondary objective 2]
3. [Secondary objective 3]

### 2.3 Exploratory Objectives

1. [Exploratory objective 1]
2. [Exploratory objective 2]

### 2.4 Hypotheses

**Primary Hypothesis**: H0: [Null hypothesis] vs. H1: [Alternative hypothesis]

**Secondary Hypotheses**: [For each secondary objective]

---

## 3. Investigation Design

### 3.1 Study Design

| Parameter | Specification |
|-----------|---------------|
| **Investigation Type** | [Randomized, Non-randomized, Single-arm] |
| **Design** | [Controlled, Uncontrolled, Blinded, Open-label] |
| **Allocation Ratio** | [e.g., 1:1] |
| **Control Type** | [Active, Placebo, Historical] |
| **Blinding** | [Double-blind, Single-blind, Open-label] |
| **Study Duration** | [Total duration] |
| **Follow-up Duration** | [Per subject] |
| **Total Sample Size** | [N = XXX] |

### 3.2 Investigation Phases

```
┌─────────────────────────────────────────────────────────┐
│ Investigation Timeline                                  │
├─────────────────────────────────────────────────────────┤
│                                                          │
│  Phase 1:     Phase 2:         Phase 3:     Phase 4:    │
│  Screening    Treatment        Follow-up     Analysis    │
│  (X days)     (X days)         (X days)      (X days)    │
│                                                          │
│  ┌──────────────────────────────────────────────────┐   │
│  │                                                  │   │
│  │  ├── Subject Enrollment                          │   │
│  │  ├── Device Implantation/Use                     │   │
│  │  ├── Assessments at Specified Intervals          │   │
│  │  └── Data Analysis and Reporting                 │   │
│  │                                                  │   │
│  └──────────────────────────────────────────────────┘   │
│                                                          │
└─────────────────────────────────────────────────────────┘
```

### 3.3 Investigation Schedule

| Visit | Day | Time Window | Procedures |
|-------|-----|-------------|------------|
| **Screening** | -X to -1 | ±X days | Informed consent, eligibility |
| **Baseline** | 0 | ±X days | Randomization, baseline assessments |
| **Treatment** | 1 to X | ±X days | Device implantation/use |
| **Follow-up 1** | X ± X | ±X days | Assessments, data collection |
| **Follow-up 2** | X ± X | ±X days | Assessments, data collection |
| **Follow-up 3** | X ± X | ±X days | Assessments, data collection |
| **End of Study** | X ± X | ±X days | Final assessments, exit |

---

## 4. Subject Selection

### 4.1 Inclusion Criteria

A subject will be eligible for inclusion if ALL of the following criteria apply:

1. Age ≥ [X] years and ≤ [Y] years
2. Diagnosis of [condition] confirmed by [method]
3. Indicated for [procedure/intervention]
4. Willing and able to provide informed consent
5. Able to comply with study procedures and follow-up
6. [Inclusion criterion 6]
7. [Inclusion criterion 7]

### 4.2 Exclusion Criteria

A subject will NOT be eligible if ANY of the following criteria apply:

1. Contraindications to device use per IFU
2. Previous [treatment/procedure] that would interfere
3. Active infection or malignancy
4. Pregnancy or breastfeeding
5. Life expectancy < [X] months
6. Enrollment in conflicting clinical investigation
7. Inability to provide informed consent
8. [Exclusion criterion 8]
9. [Exclusion criterion 9]

### 4.3 Withdrawal Criteria

A subject will be withdrawn from the investigation if:

1. Subject withdraws consent
2. Investigator determines withdrawal is in subject's best interest
3. Protocol violations that compromise subject safety
4. [Withdrawal criterion 4]

### 4.4 Subject Recruitment

**Recruitment Methods**:

- Clinic patient population
- Referrals from treating physicians
- [Other methods]

**Informed Consent Process**:

- Consent obtained by qualified investigator
- Adequate time for questions and consideration
- Consent form in subject's native language
- Copy provided to subject

---

## 5. Investigational Plan

### 5.1 Pre-Investigation Procedures

#### Screening Visit (Visit 1)

| Procedure | Purpose | Timing |
|-----------|---------|--------|
| Informed consent | Obtain permission | Before any procedures |
| Eligibility assessment | Confirm inclusion/exclusion | Before enrollment |
| Medical history | Collect baseline data | Before treatment |
| Physical examination | Assess health status | Before treatment |
| Laboratory tests | Baseline values | Before treatment |
| [Other procedure] | [Purpose] | [Timing] |

#### Baseline Visit (Visit 2)

| Procedure | Purpose | Timing |
|-----------|---------|--------|
| Randomization | Allocate treatment | Before device use |
| Baseline assessments | Collect baseline data | Before device use |
| Device preparation | Prepare for use | Per device instructions |
| [Other procedure] | [Purpose] | [Timing] |

### 5.2 Investigation Procedures

#### Treatment Visit(s)

[Describe device implantation/use procedures in detail]

**Device-Specific Procedures**:

1. Pre-procedure preparations
2. Anesthesia/sedation (if applicable)
3. Device implantation/use technique
4. Intra-procedure assessments
5. Post-procedure care

**Device Settings/Configuration**:

| Parameter | Value/Range |
|-----------|-------------|
| [Setting 1] | [Value] |
| [Setting 2] | [Value] |
| [Setting 3] | [Value] |

### 5.3 Follow-up Procedures

**Follow-up Schedule**:

| Follow-up | Timepoint | Assessments |
|-----------|-----------|-------------|
| Follow-up 1 | X days | [List assessments] |
| Follow-up 2 | X days | [List assessments] |
| Follow-up 3 | X days | [List assessments] |
| End of Study | X days | [List assessments] |

---

## 6. Investigational Product

### 6.1 Device Description

**Device Name**: [Enter device name]

**Device Classification**: [MDR class]

**Intended Purpose**: [Per IFU]

**Mode of Operation**: [Describe mechanism of action]

**Device Components**:

| Component | Description | Part Number |
|-----------|-------------|-------------|
| [Component 1] | [Description] | [Part number] |
| [Component 2] | [Description] | [Part number] |

### 6.2 Device Storage and Handling

**Storage Requirements**:

- Temperature: [X°C to Y°C]
- Humidity: [X% to Y%]
- Light protection: [Yes/No]
- Special handling: [Describe]

**Device Preparation**:

[Describe any pre-use preparation required]

### 6.3 Device Accountability

**Device Tracking**:

- Device serial numbers recorded per subject
- Device implantation/use date recorded
- Device removal/replacement date recorded (if applicable)

**Shipment Records**:

- Device shipment to sites documented
- Receipt at sites confirmed
- Return or disposal documented

---

## 7. Safety Assessment

### 7.1 Safety Definitions

**Adverse Event (AE)**: Any untoward medical occurrence in a subject...

**Serious Adverse Event (SAE)**: An adverse event that...

**Device Deficiency**: Inadequacy of a medical device...

**Unanticipated Adverse Device Effect**: Any serious adverse effect...

### 7.2 Adverse Event Collection

**Collection Methods**:

- Spontaneous subject reports
- Investigator observation
- Scheduled assessments
- [Other methods]

**AE Documentation**:

For each AE, document:
- Event description
- Onset date and time
- Severity (mild, moderate, severe)
- Seriousness criteria (if applicable)
- Relationship to device/procedure
- Action taken
- Outcome
- Causality assessment

### 7.3 SAE Reporting

**Reporting Timelines**:

| Event Type | Timeline | Recipient |
|------------|----------|-----------|
| Life-threatening SAE | Immediately (within 24 hours) | Sponsor, Ethics Committee, Competent Authority |
| Other SAE | Within 7 days | Sponsor |
| Device deficiency | Within specified timeline | Competent Authority |

**SAE Follow-up**:

- Follow-up until resolution or stabilization
- Documentation of outcome
- Assessment of relationship to device

### 7.4 Safety Monitoring

**Data Safety Monitoring Board (DSMB)**: [Yes/No]

- If Yes: Composition, meeting frequency, stopping rules

**Interim Safety Analysis**:

- Number of interim analyses: [X]
- Interim analysis timepoints: [Specify]
- Safety review committee: [Composition]

---

## 8. Effectiveness Assessment

### 8.1 Primary Endpoint

**Endpoint Definition**: [Clear, measurable definition]

**Measurement Method**: [How endpoint is measured]

**Timepoint**: [When endpoint is assessed]

**Success Criteria**: [Statistical criteria for success]

### 8.2 Secondary Endpoints

| Endpoint | Definition | Measurement | Timepoint |
|----------|------------|-------------|-----------|
| [Endpoint 1] | [Definition] | [Method] | [Timepoint] |
| [Endpoint 2] | [Definition] | [Method] | [Timepoint] |
| [Endpoint 3] | [Definition] | [Method] | [Timepoint] |

### 8.3 Exploratory Endpoints

| Endpoint | Definition | Measurement | Timepoint |
|----------|------------|-------------|-----------|
| [Endpoint 1] | [Definition] | [Method] | [Timepoint] |
| [Endpoint 2] | [Definition] | [Method] | [Timepoint] |

### 8.4 Assessment Methods

**Clinical Assessments**:

[Describe clinical assessment methods]

**Imaging Assessments** (if applicable):

[Describe imaging methods and timing]

**Laboratory Assessments**:

[Describe laboratory tests and timing]

**Patient-Reported Outcomes**:

[Describe questionnaires and timing]

---

## 9. Statistical Considerations

### 9.1 Sample Size Determination

**Sample Size Justification**:

- Primary endpoint: [Specify]
- Expected effect size: [Specify]
- Statistical power: [X%]
- Significance level: [α = X.XX]
- Sample size calculation: [Provide formula or method]
**Calculated Sample Size**: N = [XXX] per group

**Accounting for Dropouts**:

- Expected dropout rate: [X%]
- Inflated sample size: N = [XXX] per group
- Total enrollment target: N = [XXX]

### 9.2 Analysis Populations

| Population | Definition |
|------------|------------|
| **Intent-to-Treat (ITT)** | All randomized subjects |
| **Per-Protocol (PP)** | Subjects who completed without major protocol deviations |
| **Safety Population** | All subjects who received device |
| **Evaluable Population** | Subjects with sufficient data for analysis |

### 9.3 Statistical Analysis Methods

#### Primary Endpoint Analysis

- Analysis population: [ITT/PP]
- Statistical test: [e.g., Two-sample t-test]
- Confidence interval: [X%]
- Handling of missing data: [Method]

#### Secondary Endpoint Analysis

[Repeat for each secondary endpoint]

#### Safety Analysis

- Safety population: All subjects who received device
- Descriptive statistics for AEs and SAEs
- Incidence rates with [X%] confidence intervals
- Comparison to control if applicable

#### Subgroup Analyses

Pre-specified subgroups:
- Age subgroups: [<65, ≥65]
- Gender subgroups: [Male, Female]
- [Other subgroups]

### 9.4 Interim Analysis

**Interim Analysis Plan**:

- Number of interim analyses: [X]
- Interim analysis timepoints: [Specify]
- Stopping rules:
  - For efficacy: [Specify criteria]
  - For futility: [Specify criteria]
  - For safety: [Specify criteria]
- Alpha spending function: [Specify]

### 9.5 Multiplicity Adjustment

**Multiplicity Consideration**:

- Primary endpoint: [No adjustment needed/Hierarchical testing/Bonferroni]
- Secondary endpoints: [No adjustment/Adjustment method]
- Interim analyses: [Alpha spending method]

---

## 10. Data Collection and Management

### 10.1 Data Collection

**Case Report Forms (CRFs)**:

- Electronic CRF (eCRF): [Yes/No]
- System: [e.g., REDCap, Medidata Rave]
- Paper CRF backup: [Yes/No]

**Data Elements**:

[List all data elements to be collected per visit]

### 10.2 Data Management

**Data Entry**:

- Double data entry: [Yes/No]
- Edit checks: [Automated/Manual]
- Range checks: [Yes/No]
- Consistency checks: [Yes/No]

**Data Validation**:

- Source data verification: [X% of records]
- Query management: [Process]
- Data cleaning: [Process]

**Database Lock**:

- Database lock date: [Specify]
- Lock approval: [Required from whom]
- Post-lock changes: [Not allowed/With justification]

### 10.3 Data Retention and Storage

**Retention Period**: [X] years after investigation completion

**Storage Requirements**:

- Secure, access-controlled storage
- Regular backups
- Disaster recovery plan
- GDPR/privacy law compliance

---

## 11. Ethical Considerations

### 11.1 Ethics Committee Approval

**Approval Status**: [Approved/Pending]

**Ethics Committees**:

| Committee | Approval Number | Approval Date |
|-----------|-----------------|---------------|
| [EC 1] | [Number] | [Date] |
| [EC 2] | [Number] | [Date] |

### 11.2 Informed Consent

**Informed Consent Process**:

- Consent obtained by: [Qualified investigator]
- Consent language: [Subject's native language]
- Adequate time for consideration
- Opportunity for questions

**Informed Consent Elements**:

[Per ISO 14155 and applicable regulations, include all required elements]

**Informed Consent Form Attached**: [Yes/No - See Appendix X]

### 11.3 Vulnerable Populations

[Use of vulnerable populations: [Yes/No]

If Yes, describe additional protections]

### 11.4 Risk-Benefit Assessment

**Potential Benefits**:

- Direct benefits: [List]
- Indirect benefits: [List]

**Potential Risks**:

- Risks from device: [List]
- Risks from procedures: [List]
- Privacy risks: [List]

**Risk Mitigation**:

[Describe how risks are mitigated]

### 11.5 Data Protection and Privacy

**GDPR Compliance**:

- Pseudonymization of subject data
- Data processing agreements
- Subject access rights
- Data breach notification

---

## 12. Quality Control and Assurance

### 12.1 Quality Control

**Investigator Responsibilities**:

- Protocol compliance
- Accurate data collection
- Timely data entry
- AE/SAE reporting

**Site Monitoring**:

- Monitoring frequency: [e.g., Every X months]
- Monitor qualifications: [Specify]
- Monitoring activities: [Source verification, CRF review, etc.]

### 12.2 Quality Assurance

**Sponsor QA Activities**:

- Audit plan: [Frequency, sites]
- Audit scope: [All investigation activities]
- Audit reports: [Distribution, follow-up]

**External Inspections**:

- Competent authority inspections
- Ethics committee inspections
- Notified body inspections

---

## 13. Handling of Investigational Product

### 13.1 Device Accountability

**Records Required**:

- Device shipment to site
- Device receipt at site
- Device assignment to subject
- Device implantation/use
- Device removal/explant (if applicable)
- Device return or disposal

### 13.2 Device Storage

**Storage Conditions**:

- Temperature monitoring: [Continuous/Periodic]
- Temperature excursions: [Action plan]
- Security: [Access control]

### 13.3 Device Disposal

**Disposal Method**:

- Per manufacturer instructions
- Per local regulations
- Documentation of disposal

---

## 14. Records and Reports

### 14.1 Essential Documents

**Investigator Site File**:

[List all essential documents maintained at site]

**Sponsor File**:

[List all essential documents maintained by sponsor]

### 14.2 Progress Reports

**Annual Progress Report**:

- Submission: [Annually to EC, Competent Authority]
- Content: [Enrollment, safety, deviations]

**Safety Reports**:

- SAE reports: [As required]
- Annual safety report: [Yes/No]

### 14.3 Final Report

**Final Report Contents**:

[Per ISO 14155 and applicable regulations]

**Submission**:

- To Ethics Committees: [Within X days]
- To Competent Authorities: [Within X days]
- To Notified Body: [Within X days]

---

## 15. Publication Policy

### 15.1 Authorship

**Authorship Criteria**:

- Per ICMJE guidelines
- Substantial contributions to:
  - Conception/design
  - Data acquisition
  - Data analysis
  - Drafting/revising manuscript
  - Final approval

### 15.2 Publication Plan

**Target Journals**:

1. [Journal 1]
2. [Journal 2]
3. [Journal 3]

**Publication Timeline**:

- Draft manuscript: [Within X months of database lock]
- Submission: [Within X months of database lock]

### 15.3 Data Sharing

**Data Sharing Plan**:

- De-identified data: [Available on request/Not available]
- Data repository: [Specify]
- Access criteria: [Specify]

---

## 16. Appendices

### Appendix A: Informed Consent Form

[Attach informed consent form]

### Appendix B: Case Report Forms

[Attach all CRFs]

### Appendix C: Investigator Brochure

[Attach device documentation]

### Appendix D: Statistical Analysis Plan

[Attach detailed SAP]

### Appendix E: Patient Information Sheet

[Attach patient information]

### Appendix F: Ethics Committee Approvals

[Attach approval letters]

### Appendix G: Regulatory Approvals

[Attach regulatory correspondence]

---

## Document Approval

| Role | Name | Signature | Date |
|------|------|-----------|------|
| **Principal Investigator** | | | |
| **Sponsor Representative** | | | |
| **Medical Monitor** | | | |
| **Statistician** | | | |

---

**END OF CLINICAL INVESTIGATION PLAN TEMPLATE**

---

## Template Usage Notes

1. **Customization Instructions**:
   - Adapt to device-specific requirements
   - Adjust statistical methods for endpoints
   - Modify timelines and visit schedules

2. **Regulatory Compliance**:
   - Ensure compliance with ISO 14155:2020
   - Comply with regional clinical trial regulations
   - Obtain all required approvals before initiation

3. **Protocol Amendments**:
   - Document all protocol amendments
   - Obtain approval for amendments before implementation
   - Maintain version history
